Evidence map›Paper›PMID 34422639›Full record

ArticleFrontiers in oncology2021

Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma.

Hejuan Hu, Bai Ling, Yuhan Shi, Haohao Wu, Bingying Zhu, Yiling Meng, Guo-Ming Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Hejuan HuSuzhou Key Laboratory for Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China.
Bai LingDepartment of Pharmacy, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Yuhan ShiDepartment of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Haohao WuDepartment of Oncology, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Bingying ZhuSuzhou Key Laboratory for Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China.
Yiling MengSuzhou Key Laboratory for Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China.
Guo-Ming ZhangDepartment of Laboratory Medicine, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang, China.
Suzhou Vocational Health College · CNFuyang City People's Hospital · CNShanghai Public Health Clinical Center · CNXuzhou Medical College · CNYancheng First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate plasma exosome-derived SUMO-specific protease (SENP)1 levels and assess their prognostic value in melanoma. PATIENTS AND

methodsWe extracted exosomes from the plasma of 126 melanoma patients, and identified them with transmission electron microscopy, nanoparticle tracking analysis and western blotting. The plasma exosome-derived SENP1 levels of melanoma patients and healthy controls were detected with ELISA.

resultsPlasma exosome-derived SENP1 levels in melanoma patients were significantly upregulated than in healthy controls (

conclusionsMelanoma patients with higher plasma exosome-derived SENP1 levels had worse DFS and OS. The plasma exosome-derived SENP1 levels may be a potential prognostic predictor for 3-year DFS and 3-year OS of melanoma.

Indexed as

exosomesmelanomaprognostic predictorSENP1SUMO

Identifiers

PMID34422639
PMCPMC8374070
OpenAlexW3188431076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.